Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-04-13
2010-11-30
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050
Reexamination Certificate
active
07842691
ABSTRACT:
Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy. Specific second active ingredients are capable of affecting or improving blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4810643 (1989-03-01), Souza
patent: 4999291 (1991-03-01), Souza
patent: 5059595 (1991-10-01), LeGrazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5288487 (1994-02-01), Kawashima et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5463063 (1995-10-01), Muller
patent: 5528823 (1996-06-01), Rudy et al.
patent: 5580755 (1996-12-01), Souza
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5605914 (1997-02-01), Muller
patent: 5632984 (1997-05-01), Wong et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5643915 (1997-07-01), Andrulis et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller
patent: 5733566 (1998-03-01), Lewis
patent: 5736570 (1998-04-01), Muller
patent: 5770589 (1998-06-01), Billson
patent: 5801195 (1998-09-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6001368 (1999-12-01), Jenks
patent: 6011050 (2000-01-01), Muller et al.
patent: 6015803 (2000-01-01), Wirostko
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6075041 (2000-06-01), Muller
patent: 6130226 (2000-10-01), Muller et al.
patent: 6180644 (2001-01-01), Muller et al.
patent: 6200987 (2001-03-01), Muller
patent: 6214857 (2001-04-01), Muller et al.
patent: 6218369 (2001-04-01), Bombardelli et al.
patent: 6225348 (2001-05-01), Paulson
patent: 6228879 (2001-05-01), Green et al.
patent: 6262101 (2001-07-01), Muller et al.
patent: 6284780 (2001-09-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6429221 (2002-08-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6479554 (2002-11-01), Muller et al.
patent: 6518281 (2003-02-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6656964 (2003-12-01), Muller et al.
patent: 6667316 (2003-12-01), Man et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 6699899 (2004-03-01), Man et al.
patent: 6844359 (2005-01-01), Muller
patent: 6911464 (2005-06-01), Man et al.
patent: 6962940 (2005-11-01), Muller et al.
patent: 7034052 (2006-04-01), Muller et al.
patent: 7173058 (2007-02-01), Muller et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045726 (2003-03-01), Muller
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0114516 (2003-06-01), Muller et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0187052 (2003-10-01), Muller et al.
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0006096 (2004-01-01), Muller et al.
patent: 2004/0019106 (2004-01-01), Muller et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0147588 (2004-07-01), Man et al.
patent: 2004/0167174 (2004-08-01), Man et al.
patent: 2004/0167199 (2004-08-01), Muller et al.
patent: 2004/0259873 (2004-12-01), Man et al.
patent: 2005/0014727 (2005-01-01), Muller et al.
patent: 2006/0025457 (2006-02-01), Muller et al.
patent: 2006/0084815 (2006-04-01), Muller et al.
patent: 9-500872 (1997-01-01), None
patent: 11-286455 (1999-10-01), None
patent: 2001-525816 (2001-12-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 97/08143 (1997-03-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 99/06041 (1999-02-01), None
patent: WO 01/34606 (2001-05-01), None
patent: WO 01/45702 (2001-06-01), None
patent: WO 01/87306 (2001-11-01), None
patent: WO 01/87307 (2001-11-01), None
patent: WO 03/080048 (2003-10-01), None
patent: WO 03/080049 (2003-10-01), None
patent: WO 03/097040 (2003-11-01), None
patent: WO 2004/045597 (2004-06-01), None
patent: WO 2004/054501 (2004-07-01), None
Raza et al (Pentoxifylline, Ciproflaxacin, and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients; Malignancy, Hematology, 2000; 5(4): 275-284.
Gore et al. Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches, Cancer Control (2008), vol. 15, No. 4, supplement, printed pp. 1-10.
Celgene Corp/De/-10-K Annual Report, Dec. 31, 2000, printed pp. 1-165.
Vippagunta et al. (Crystalline Solids, Adv Drug Deliv Rev May 16, 2001; 48(1): 3-26.
European Search Report for EP 03 72 6263 dated Sep. 15, 2008.
Mundle, Suneel D. et al., “Correlation of tumor necrosis factor α (TNEFα) with high Caspase 3-like activity in myelodysplastic syndromes,”Cancer Letters, 1999, 140:201-207.
Schwarz, E.M. et al., “Anti-TNF-α therapy as a clinical intervention for periprosthetic osteolysis,”Arthritis Research, 2000, 2:165-168.
Komatsu, N. et al., “Erythropoietin Rapidly Induces Tyrosine Phosphorylation in the Human Erythropoietin-Dependent Cell Line, UT-7,”Blood, 1992, 80(1):53-59.
Office Communication in corresponding Japanene Appl. No. 2004-545793 dated May 26, 2009.
Reza, S. et al., “Tumor Necrosis Factor-α Levels Decrease with Anticytokine Therapy in Patients with Myelodysplastic Syndromes,”Journal of Interferon and Cytokine Research, 1998, 18:871-877.
Raza, A. et al., “Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone,”Blood, 2000, 95(5):1580-1587.
Official Communication in corresponding European Patent Appl. No. 03 726 263.1 dated Mar. 11, 2010.
Office Communication in corresponding Chinese Appl. No. 200480043336.0 dated Feb. 20, 2009.
Office Communication in corresponding Mexican Appl. No. PA/a/2005/003889 dated Feb. 23, 2009.
Beazley et al., 1985, “Malignant stricture at the confluence of the biliary tree: diagnosis and management,”Surg. Annu.17:125-41.
Bellamy et al., 2001, “Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes,” Blood 97:1427-1434.
Bennett et al., 1985, “Proposed revised criteria for the classification
Betton Timothy E
Celgene Corporation
Jones Day
Padmanabhan Sreeni
LandOfFree
Method for the treatment of myelodysplastic syndromes using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of myelodysplastic syndromes using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of myelodysplastic syndromes using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168974